Associations - ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
ROS1 fusion	Melanoma	ROS1 fusion	Melanoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ROS1 fusion	Melanoma	ROS1 fusion	Melanoma	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	repotrectinib Sensitive: A2 - Guideline repotrectinib Sensitive : A2	repotrectinib Sensitive: A2 - Guideline repotrectinib Sensitive : A2
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	AB-106 Sensitive: B - Late Trials AB-106 Sensitive : B	AB-106 Sensitive: B - Late Trials AB-106 Sensitive : B
ROS1 wild-type	Lung Non-Small Cell Squamous Cancer	ROS1 wild-type	Lung Non-Small Cell Squamous Cancer	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B
ROS1 wild-type	Lung Non-Squamous Non-Small Cell Cancer	ROS1 wild-type	Lung Non-Squamous Non-Small Cell Cancer	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B
ROS1 wild-type	Lung Non-Squamous Non-Small Cell Cancer	ROS1 wild-type	Lung Non-Squamous Non-Small Cell Cancer	nivolumab + bevacizumab Sensitive: B - Late Trials nivolumab + bevacizumab Sensitive : B	nivolumab + bevacizumab Sensitive: B - Late Trials nivolumab + bevacizumab Sensitive : B
ROS1 positive	Solid Tumor	ROS1 positive	Solid Tumor	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1
ROS1 fusion	Solid Tumor	ROS1 fusion	Solid Tumor	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	repotrectinib Sensitive: C2 – Inclusion Criteria repotrectinib Sensitive : C2	repotrectinib Sensitive: C2 – Inclusion Criteria repotrectinib Sensitive : C2
CD74-ROS1 fusion	Non Small Cell Lung Cancer	CD74-ROS1 fusion	Non Small Cell Lung Cancer	AB-106 Sensitive: C2 – Inclusion Criteria AB-106 Sensitive : C2	AB-106 Sensitive: C2 – Inclusion Criteria AB-106 Sensitive : C2
ROS1 positive	Lung Cancer	ROS1 positive	Lung Cancer	lorlatinib Sensitive: C2 – Inclusion Criteria lorlatinib Sensitive : C2	lorlatinib Sensitive: C2 – Inclusion Criteria lorlatinib Sensitive : C2
ROS1 positive	Solid Tumor	ROS1 positive	Solid Tumor	unecritinib Sensitive: C2 – Inclusion Criteria unecritinib Sensitive : C2	unecritinib Sensitive: C2 – Inclusion Criteria unecritinib Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	AB-106 Sensitive: C2 – Inclusion Criteria AB-106 Sensitive : C2	AB-106 Sensitive: C2 – Inclusion Criteria AB-106 Sensitive : C2
ROS1 rearrangement	Lung Cancer	ROS1 rearrangement	Lung Cancer	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	brigatinib Sensitive: C2 – Inclusion Criteria brigatinib Sensitive : C2	brigatinib Sensitive: C2 – Inclusion Criteria brigatinib Sensitive : C2
ROS1 rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ROS1 rearrangement	Lung Non-Squamous Non-Small Cell Cancer	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	unecritinib Sensitive: C2 – Inclusion Criteria unecritinib Sensitive : C2	unecritinib Sensitive: C2 – Inclusion Criteria unecritinib Sensitive : C2
ROS1 positive	Mesothelioma	ROS1 positive	Mesothelioma	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2	U3-1402 Sensitive: C2 – Inclusion Criteria U3-1402 Sensitive : C2

ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

Associations(161)

Associations
(161)